Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study Of NB1011 Administered Intravenously Daily For 5 Days Every 4 Weeks In Fluoropyrimidine-Resistant Metastatic Or Relapsed Colorectal Cancers

NCT00031616 is registered in ClinicalTrials.gov with NewBiotics as lead sponsor.

NCT NCT00031616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00031616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study Of NB1011 Administered Intravenously Daily For 5 Days Every 4 Weeks In Fluoropyrimidine-Resistant Metastatic Or Relapsed Colorectal Cancers
Lead sponsor
NewBiotics
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 31, 2001
Completion date
Not reported
Enrollment
Not reported
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer